Connor, Clark & Lunn Investment Management (CC&L)
LGND icon

Connor, Clark & Lunn Investment Management (CC&L)’s Ligand Pharmaceuticals LGND Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Sell
3,291
-1,652
-33% -$389K ﹤0.01% 1185
2026
Q1 		$987K Sell
4,943
-1,090
-18% -$216K ﹤0.01% 1159
2025
Q4 		$1.14M Buy
+6,033
New +$1.16M ﹤0.01% 1094
2025
Q2 		– Sell
-2,944
Closed -$310K – 1606
2025
Q1 		$310K Sell
2,944
-20,819
-88% -$2.35M ﹤0.01% 1246
2024
Q4 		$2.55M Sell
23,763
-3,200
-12% -$362K 0.01% 662
2024
Q3 		$2.7M Buy
26,963
+9,667
+56% +$973K 0.01% 601
2024
Q2 		$1.46M Sell
17,296
-6,928
-29% -$551K 0.01% 750
2024
Q1 		$1.77M Buy
+24,224
New +$1.79M 0.01% 708
2020
Q2 		– Sell
-5,490
Closed -$249K – 1112
2020
Q1 		$249K Buy
+5,490
New +$311K ﹤0.01% 831
2019
Q1 		– Sell
-14,146
Closed -$1.2M – 989
2018
Q4 		$1.2M Buy
14,146
+12,703
+880% +$1.35M 0.01% 516
2018
Q3 		$247K Buy
+1,443
New +$218K ﹤0.01% 815
2015
Q1 		– Sell
-11,061
Closed -$367K – 595
2014
Q4 		$367K Sell
11,061
-8,175
-42% -$266K ﹤0.01% 434
2014
Q3 		$564K Sell
19,236
-8,336
-30% -$277K ﹤0.01% 374
2014
Q2 		$1.14M Sell
27,572
-51,616
-65% -$2.09M 0.01% 313
2014
Q1 		$3.67M Buy
79,188
+41,517
+110% +$1.73M 0.03% 194
2013
Q4 		$1.31M Buy
37,671
+1,283
+4% +$41.8K 0.01% 324
2013
Q3 		$1.01M Buy
36,388
+6,252
+21% +$176K 0.01% 269
2013
Q2 		$742K Buy
+30,136
New +$542K 0.01% 303

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s LGND Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Ligand Pharmaceuticals (LGND) stake by 33% in Q2 2026, selling an estimated $389K and leaving 3,291 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1185.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in LGND in Q2 2013 and has held it in 18 quarters since. The position peaked at $3.67M in Q1 2014. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 3,291 shares of Ligand Pharmaceuticals worth $1.04M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 1,652 Ligand Pharmaceuticals shares in Q2 2026, an estimated $389K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1185 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 18 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Ligand Pharmaceuticals position peaked at $3.67M in Q1 2014.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.